AURICULARUM (oxytetracycline, polymyxin B, dexamethasone, nystatin), anti-infective and corticosteroid in combination
Reason for request
Low clinical benefit in the topical treatment of chronic otitis for perioperative use
- AURICULARUM has been granted a marketing authorisation for the topical treatment of chronic otitis: for pre-operative draining and for post-operative use in the petromastoid canal, with or without tympanoplasty.
Fluoroquinolone ear drops are the first-line treatments of chronic otitis. The role of AURICULARUM, containing an antifungal agent combined with two non-fluoroquinolone antibiotics, is limited in the therapeutic strategy for otitis externa; it should be reserved for cases of acute otitis externa of fungal or combined fungal and bacterial origin.